Dec 13, 2019
PTC Therapeutics Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
Nov 29, 2019
PTC Therapeutics Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
Oct 31, 2019
PTC Therapeutics Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
Oct 29, 2019
PTC Therapeutics Reports Third Quarter 2019 Financial Results and Provides a Corporate Update
Oct 23, 2019
PTC Therapeutics Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
Oct 15, 2019
PTC Therapeutics to Host Conference Call to Discuss Third Quarter 2019 Financial Results
Oct 04, 2019
PTC Therapeutics Announces New Real-World Analysis Demonstrating Translarna(TM) (ataluren) Slows Disease Progression in Patients with Duchenne Muscular Dystrophy
Sep 20, 2019
PTC Therapeutics Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
Sep 18, 2019
PTC Therapeutics Announces Pricing of Private Offering of Convertible Senior Notes
Sep 18, 2019
PTC Therapeutics Announces Pricing of Public Offering of Common Stock
Sep 17, 2019
PTC Therapeutics Announces Proposed Private Offering of Convertible Senior Notes
Aug 06, 2019
PTC Therapeutics Reports Second Quarter 2019 Financial Results and Provides a Corporate Update
Aug 05, 2019
PTC Therapeutics Expands Presence in New Jersey by Securing State-of-the-Art Biologics Facility
Jul 23, 2019
PTC Therapeutics to Host Conference Call to Discuss Second Quarter 2019 Financial Results
Jun 28, 2019
PTC Provides Update on Translarna(TM) (ataluren) Application for Label Expansion
Jun 07, 2019
PTC Therapeutics Receives FDA Approval for the Expansion of the EMFLAZA® (deflazacort) Labeling to Include Patients 2-5 Years of Age
Jun 03, 2019
PTC Therapeutics Promotes Emily Hill to Chief Financial Officer
May 30, 2019
PTC Therapeutics to Participate at Upcoming Investor Conference
May 03, 2019
PTC Therapeutics Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
May 02, 2019
PTC Therapeutics Reports First Quarter 2019 Financial Results and Provides a Corporate Update